ReviewJournal of leukocyte biology2017

Dual inhibition of complement and Toll-like receptors as a novel approach to treat inflammatory diseases-C3 or C5 emerge together with CD14 as promising targets.

Andreas Barratt-Due et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.